ADB-FUBINACA

From Wikipedia, the free encyclopedia
Jump to: navigation, search
ADB-FUBINACA
ADB-FUBINACA.png
Systematic (IUPAC) name
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
Clinical data
Identifiers
1445583-51-6 YesY
ChemSpider 29763706
Chemical data
Formula C21H23FN4O2
382.43 g/mol

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013.[1] The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982, with a Ki value of 0.36nM at CB1.[2] ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved.[citation needed] Nothing is known of the pharmacological activity of ADB-FUBINACA in humans or other animals.

See also[edit]

References[edit]

  1. ^ Uchiyama, N.; Matsuda, S.; Kawamura, M.; Kikura-Hanajiri, R.; Goda, Y. (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products". Forensic Toxicology. doi:10.1007/s11419-013-0182-9.  edit
  2. ^ Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982